Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR2251 in Primary Gout and Hyperuricemia
NCT07498647Phase 2Not yet recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of BR2251 in gout, hyperuricemia, sponsored by BioRay Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
BR2251
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT07498647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498647.